MetLife Investment Management’s Assembly Biosciences ASMB Stock Holding History

MetLife Investment Management’s Portfolio ASMB Stock Details ASMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$162K	Buy	+5,885	New	+$160K	﹤0.01%	2529
2020 Q4	–	Sell	-1,087	Closed	-$214K	–	2274
2020 Q3	$214K	Hold	1,087	–	–	﹤0.01%	1824
2020 Q2	$304K	Hold	1,087	–	–	﹤0.01%	1645
2020 Q1	$193K	Buy	1,087 +273	+34%	+$58.5K	﹤0.01%	1717
2019 Q4	$200K	Hold	814	–	–	﹤0.01%	1979
2019 Q3	$96K	Hold	814	–	–	﹤0.01%	2311
2019 Q2	$132K	Sell	814 -1,627	-67%	-$309K	﹤0.01%	2251
2019 Q1	$577K	Buy	2,441 +1,627	+200%	+$412K	﹤0.01%	1976
2018 Q4	$221K	Hold	814	–	–	﹤0.01%	1855
2018 Q3	$363K	Buy	814 +214	+36%	+$100K	﹤0.01%	1739
2018 Q2	$282K	Buy	+600	New	+$317K	﹤0.01%	1742
2018 Q1	–	Sell	-600	Closed	-$326K	–	2187
2017 Q4	$326K	Buy	+600	New	+$272K	﹤0.01%	1659

Other funds holding ASMB

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

MetLife Investment Management's ASMB Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Assembly Biosciences (ASMB) in Q2 2026: 5,885 shares worth $162K. The stake represents ﹤0.01% of the portfolio and ranks #2529 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in ASMB as recently as Q3 2020.

MetLife Investment Management first reported a position in ASMB in Q4 2017 and has held it in 12 quarters since. The position peaked at $577K in Q1 2019. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

MetLife Investment Management held 5,885 shares of Assembly Biosciences worth $162K as of Q2 2026.
Assembly Biosciences was a new MetLife Investment Management position in Q2 2026.
Assembly Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2529 holding.
MetLife Investment Management first reported a position in Assembly Biosciences in Q4 2017 and has held it in 12 quarters since.
MetLife Investment Management's Assembly Biosciences position peaked at $577K in Q1 2019.
93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.